Cardiologist explains benefits of GLP-1 drugs go beyond just weight loss: ‘Future of how we treat heart, liver…’
Everyone’s talking about weight loss drugs like Ozempic, Wegovy and Mounjaro and their implications on weight loss – but their benefits go way beyond that.
Your gym membership just got competition — weight-loss drug Wegovy launches in Malaysia
KUALA LUMPUR, Jan 15 — Novo Nordisk today announced that its weight-loss drug, Wegovy (semaglutide 2.4mg), is now officially available in Malaysia, offering a new treatment option for adults living with obesity or who are overweight with related health issues. The launch comes as Malaysia grapples with a growing health crisis. The latest National Health […]
Samsung Epis targets nine additional biosimilars, drug development expansion in growth strategy
Kim Kyung-ah, president and CEO of Samsung Epis Holdings and Samsung Bioepis, answers questions from the Korean reporters at a press event held on the sidelines of the 44th J.P. Morgan Health Care Conference in San Francisco on Jan. 14. [SAMSUNG EPIS HOLDINGS] SAN FRANCISCO — Samsung Epis Holdings, the new holding company for […]
STAT+: Novo Nordisk Foundation gives $850M to nonprofit to help commercialize research in Europe
Five years ago, the Novo Nordisk Foundation spun out a nonprofit called the BioInnovation Institute with the aim of identifying promising research and building companies around it, while at the same time developing Denmark’s startup ecosystem. On Thursday, the foundation announced it was giving an additional $850 million to the institute over the next 10 […]
‘I regret not discovering GLP-1s sooner,’ says Oprah Winfrey
Oprah Winfrey has expressed regret for not discovering GLP-1s and starting her weight loss journey sooner, which would have allowed her to arrive at the place she is now – a place of contentment with her weight and overall well-being. The former host of The Oprah Winfrey Show is on a press tour to promote […]
Healthy Returns: Novo Nordisk CEO on GLP-1 pricing, and more insights from the JPM conference – CNBC
Healthy Returns: Novo Nordisk CEO on GLP-1 pricing, and more insights from the JPM conference CNBC On Day 3 of JPM, pharma threads a needle with the White House, and Novo Nordisk has an eye on M&A statnews.com Novo’s CEO Is Ready to Go ‘Very Big’ in Hunt for Obesity Deals Bloomberg JPM26, Day 2: After ceding obesity […]
STAT+: Pharmacy compounder files antitrust lawsuit against Eli Lilly and Novo Nordisk
In the latest fracas over the burgeoning market for weight loss drugs, a compounding pharmacy has filed a lawsuit accusing Eli Lilly and Novo Nordisk of using anticompetitive tactics to prevent it from serving patients. Strive Specialties claimed the drugmakers entered into exclusive agreements with telehealth providers, which were then barred from working with compounders; […]
Celltrion to internalize U.S. production with $18B investment in New Jersey facility
Celltrion CEO Seo Jin-seok delivers a keynote speech on the company’s future road map at the 44th J.P. Morgan Health Care Conference held in San Francisco on Jan.13. [CELLTRION] SAN FRANCISCO — Celltrion plans to invest $18 billion over the next decade in its recently acquired U.S. manufacturing facility in Branchburg, New Jersey, expanding […]
[Review] Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits
GLP-1 receptor agonists were initially developed to treat type 2 diabetes and have had a transformative effect on its therapy, and are highly effective for glycaemic control, with the added benefit of bodyweight reduction and a low risk of causing hypoglycaemia. GLP-1 receptor agonists reduce risks for major adverse cardiovascular events (eg, non-fatal myocardial infarction, […]
GLP-1 obesity drugs cleared of suicide warning
Years after approving three glucagon-like peptide-1 (GLP-1) receptor agonists to treat obesity, the U.S. FDA is acknowledging that the drugs don’t have the same risk seen with older weight-loss medicines. Citing its post-market evaluation that found no increased risk of suicidal ideation or behavior, the U.S. FDA is requesting that the risk be removed from […]